HCW Biologics Q3 net loss narrows 29% to $3.22 million
HCWB•HCW Biologics’ third-quarter 2026 net loss narrowed 29% year over year to $3.22 million, while revenue more than tripled to $55,463. The company secured up to $10 million in debt financing and expects to complete HCW9302 Phase 1 and determine a recommended Phase 2 dose in the first quarter of 2027.
1. Quarterly results
HCW Biologics’ third-quarter 2026 net loss narrowed 29% year over year to $3.22 million. Revenue more than tripled year over year to $55,463.
2. Financing and trial
In November, the company secured up to $10 million in debt financing, including $3 million received at closing before transaction costs. HCW Biologics expects to complete HCW9302 Phase 1 and determine a recommended Phase 2 dose in the first quarter of 2027.




